Literature DB >> 17069929

Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.

Veli-Pekka Ranta1, Arto Urtti.   

Abstract

Basic biological research has provided new approaches to treat severe diseases of the retina and choroid, such as age related macular degeneration. Although it is possible to deliver drugs from a subconjunctival drug depot to the retina and choroid, the barriers and kinetics of this route of drug administration are not well known. In this review we investigate the pharmacokinetic aspects of transscleral drug delivery into the posterior eye with emphasis on pharmacokinetic modeling. The existing simulation models related to the transscleral drug delivery are reviewed and future directions for the model development are discussed. In addition, a new simulation model for the transscleral drug delivery based on permeability data is introduced. This compartmental model contains several ocular tissues (sclera, choroid, retinal pigment epithelium and vitreous) and it takes into account the clearance of the drug via choroidal circulation. The model is used to simulate the vitreous delivery of macromolecules based on the available data on FITC-dextran 70 kDa.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17069929     DOI: 10.1016/j.addr.2006.07.025

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  31 in total

1.  Melt-Cast Noninvasive Ocular Inserts for Posterior Segment Drug Delivery.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Akshaya Tatke; Karthik Yadav Janga; Prakash Bhagav; Soumyajit Majumdar
Journal:  J Pharm Sci       Date:  2017-08-01       Impact factor: 3.534

2.  Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow.

Authors:  Ram K Balachandran; Victor H Barocas
Journal:  Pharm Res       Date:  2008-08-05       Impact factor: 4.200

Review 3.  New techniques for drug delivery to the posterior eye segment.

Authors:  Esther Eljarrat-Binstock; Jacob Pe'er; Abraham J Domb
Journal:  Pharm Res       Date:  2010-02-13       Impact factor: 4.200

4.  Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice.

Authors:  Chang Rae Rho; Seungbum Kang; Ki Cheol Park; Keum-Jin Yang; Hyunsu Choi; Won-Kyung Cho
Journal:  J Ocul Pharmacol Ther       Date:  2015-02       Impact factor: 2.671

5.  Physicochemical and biological characterization of sustained isopropyl unoprostone-release device made of poly(ethyleneglycol) dimethacrylates.

Authors:  Nobuhiro Nagai; Yasuko Izumida; Yoshimasa Yamazaki; Hirokazu Kaji; Junichi Kawasaki; Matsuhiko Nishizawa; Toshiaki Abe
Journal:  J Mater Sci Mater Med       Date:  2017-05-22       Impact factor: 3.896

6.  Novel nanoparticulate gel formulations of steroids for the treatment of macular edema.

Authors:  Sai H S Boddu; Jwala Jwala; Ravi Vaishya; Ravinder Earla; Pradeep K Karla; Dhananjay Pal; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2010-02       Impact factor: 2.671

7.  In vivo ocular fluorophotometry: delivery of fluoresceinated dextrans via transscleral diffusion in rabbits.

Authors:  Damian E Berezovsky; Samirkumar R Patel; Bernard E McCarey; Henry F Edelhauser
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-01       Impact factor: 4.799

Review 8.  Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

Authors:  Uday B Kompella; Aniruddha C Amrite; Rashmi Pacha Ravi; Shelley A Durazo
Journal:  Prog Retin Eye Res       Date:  2013-04-17       Impact factor: 21.198

9.  Modeling of corneal and retinal pharmacokinetics after periocular drug administration.

Authors:  Aniruddha C Amrite; Henry F Edelhauser; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

10.  Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin.

Authors:  Shwu-Jiuan Sheu; Youn-Shen Bee; Yi-Ling Ma; Guei-Sheung Liu; Hsiu-Chen Lin; Tse-Liang Yeh; Jau-Chen Liou; Ming-Hong Tai
Journal:  Mol Vis       Date:  2009-09-18       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.